Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a growth of 20% compared to the previous year[66]. - The company’s operating revenue for 2022 was CNY 1,485,693,905, representing a 21.75% increase compared to CNY 1,220,275,240 in 2021[23]. - The net profit attributable to shareholders of the listed company for 2022 was CNY 291,463,635, a 40.77% increase from CNY 207,047,711 in 2021[23]. - The company reported a total revenue of 3,783.06 million for the year 2022[51]. - The company achieved a gross margin of 45%, up from 40% in the previous year, due to cost optimization measures[15]. - The company reported a significant increase in non-recurring gains and losses, with a net profit of CNY 316,554,577.34 in 2022, compared to CNY 10,191,272.43 in 2021, marking a 2,965.93% increase[23]. - The company reported a total revenue of 127,854.8 million CNY for the year, with a net profit of 41,712.38 million CNY, indicating a strong financial performance[131]. - The company reported a significant increase in revenue, reaching 1.2 billion CNY in 2022, representing a year-over-year growth of 15%[71]. - The company reported a total revenue of 52,558,047 in 2021, indicating a significant growth trajectory[60]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[15]. - The company is focused on expanding its market presence in Southeast Asia, targeting a 10% market share by 2025[53]. - The company is exploring market expansion opportunities in both domestic and international markets to increase its footprint[54]. - The company is actively pursuing market expansion, targeting both domestic and international markets to increase its footprint in the dental care sector[57]. - The company is exploring potential mergers and acquisitions to strengthen its market position[134]. - The company is exploring strategic opportunities for market expansion and potential mergers or acquisitions to bolster its growth trajectory[180]. - The company is focusing on expanding its product offerings in the renewable energy sector, responding to increasing demand and orders in this area[180]. Research and Development - Investment in R&D increased by 30%, focusing on new technologies in molecular diagnostics and precision medicine[15]. - The company has a mature and effective R&D system, with increased investment in R&D and recruitment of skilled personnel, leading to improved product quality and cost-effectiveness[48]. - The company is committed to enhancing its research and development capabilities to drive innovation in medical technology[51]. - The company has invested 100 million CNY in R&D for new technologies and product development in 2023[72]. - The company is investing in research and development of innovative medical technologies and solutions[135]. - The company has invested in advanced research and development, focusing on innovative dental care solutions to meet evolving consumer needs[57]. - The company is focusing on R&D and aligning products with market demand to navigate economic uncertainties and promote high-quality development[177]. Product Development and Innovation - The company is set to launch three new products in the next quarter, which are anticipated to contribute an additional 200 million RMB in revenue[15]. - New product developments are underway, focusing on innovative medical technologies aimed at enhancing patient care[54]. - The company is focusing on the development of new products, including next-generation DNA sequencing and genetic testing services[133]. - The company is actively developing new medical devices and instruments, including dental equipment and surgical implants, to enhance its product offerings[59]. - The company is focusing on the development of new products and technologies, particularly in the PVP sector, to enhance market competitiveness[181]. - The company has completed the development of a high-efficiency method for analyzing sample methylation levels, which enhances operational efficiency and expands business scope[112]. - The company has developed a new preservation solution for COVID-19 virus sampling, ensuring the accuracy of virus extraction and testing results[108]. Governance and Compliance - The company emphasizes the importance of accurate and complete financial reporting, ensuring accountability from its executives[3]. - The report highlights the company's commitment to compliance with regulatory standards and quality management practices[12]. - The company has obtained various quality certifications, including the Drug Production License and GMP certification, ensuring compliance with quality management standards[49]. - The company is committed to strict compliance with national regulations to mitigate operational risks associated with policy changes[176]. Operational Efficiency - The company aims to enhance its operational efficiency and maximize asset utilization across its properties[51]. - The company aims to reduce operational costs by 15% through improved efficiency measures[53]. - The company is committed to enhancing its operational performance through resource integration and improved efficiency to reduce goodwill impairment risks[176]. - The company is focusing on improving the quality of its products through advanced production techniques, aligning with international standards such as USP, EP, and JP[107]. User Engagement and Customer Satisfaction - User data showed an increase in active users, reaching 2 million, which is a 15% increase year-over-year[15]. - Customer satisfaction ratings improved to 90%, reflecting the effectiveness of recent service enhancements[53]. - User data indicates a growing customer base, with a 20% increase in active users compared to the previous year, totaling approximately 500,000 users[76]. - User data indicates a growing demand for dental care products, with an increasing trend in consumer awareness regarding oral hygiene[56]. Risks and Challenges - The company faces significant risks from national policy changes in the healthcare sector, which could adversely affect operational performance if strategies are not adjusted accordingly[176]. - Rising labor costs are a concern as employee numbers and compensation levels increase; if revenue does not grow correspondingly, this could negatively affect future performance[176]. - The company reported a non-recurring loss of 19 million yuan in the first half of the year, which needs to be addressed to improve financial health[179]. Intellectual Property - The company holds multiple trademarks, including "博爱新开源" and "WHIVIDONE," with registration numbers ranging from 5418542 to 13675232, valid until 2029 and beyond[55]. - The company has established a strong intellectual property portfolio, which is essential for competitive advantage in the healthcare and consumer goods markets[55]. - The company has secured a total of 20 patents, with a mix of invention and utility model patents, showcasing its commitment to enhancing its technological capabilities[62]. Sustainability and Ethical Practices - The company is committed to sustainability and is exploring eco-friendly product options to meet consumer demand[58]. - A commitment to sustainability and ethical practices is being prioritized in the company's long-term strategy[54].

Financial Performance - The company's revenue for Q1 2023 was ¥363,003,583.47, representing a 16.77% increase compared to ¥310,869,875.29 in the same period last year[4] - Net profit attributable to shareholders reached ¥119,979,801.13, a significant increase of 267.98% from ¥32,604,859.37 year-on-year[4] - Basic earnings per share increased to ¥0.39, up 290.00% from ¥0.10 in the same quarter last year[4] - Operating profit significantly improved to ¥154,728,205.01, up from ¥44,095,556.29, marking an increase of 250.5%[27] - Net profit for the current period was ¥119,313,647.55, compared to ¥31,554,115.42 in the previous period, reflecting a growth of 278.5%[27] - The company reported a total comprehensive income of ¥119,468,991.30, compared to ¥31,741,429.97 in the previous period, an increase of 276.5%[28] Cash Flow - The net cash flow from operating activities was ¥104,812,243.03, a 159.99% improvement from a negative cash flow of ¥174,723,246.02 in the previous year[4] - Cash inflow from operating activities totaled ¥357,576,096.52, slightly down from ¥360,232,183.38 in the previous period[30] - The company reported a total cash outflow of ¥73,643,622.61 for the quarter, compared to a cash outflow of ¥363,589,918.13 in the previous year[31] - Total cash outflow from investing activities was ¥181,329,902.33, compared to ¥48,915,893.14 in the same period last year, resulting in a net cash flow from investing activities of -¥180,410,623.98[31] - Cash inflow from financing activities amounted to ¥6,500,000.00, an increase from ¥2,039,500.00 in Q1 2022, leading to a net cash flow from financing activities of ¥3,702,270.27[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,793,407,270.55, reflecting a 2.15% increase from ¥3,713,523,107.73 at the end of the previous year[4] - The total liabilities decreased from 596,286,950.89 yuan at the beginning of the year to 557,069,733.15 yuan[25] - The company's total equity increased from 3,117,236,156.84 yuan to 3,236,337,537.40 yuan[25] - The company held long-term equity investments valued at 114,691,584.83 yuan, up from 14,393,865.83 yuan at the beginning of the year[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 16.232 million[13] - The largest shareholder, Wang Donghu, holds 8.66% of shares, amounting to 28,063,481 shares, with 22,441,972 shares pledged[13] - Wang Jianqiang, the second-largest shareholder, owns 4.86% of shares, totaling 15,731,091 shares, with 8,274,390 shares pledged[13] - The top ten shareholders include various institutional investors, with the largest being CITIC Securities and Wuhu Great Wall Guolong Investment Management Co., holding 3.95% and 3.91% respectively[13] - The total number of restricted shares at the beginning of the period was 56,497,025, with 14,095,217 shares released during the period[17] Strategic Initiatives - The company is actively managing its shareholder structure, with a focus on maintaining control among key stakeholders[14] - The report indicates a strategic focus on retaining key executives through share lock-up agreements[17] - The company is preparing for future growth by ensuring a stable shareholder base and aligning interests with management through equity incentives[18] - The company acquired a 13% stake in Suzhou Dongsheng Xingye Scientific Instrument Co., Ltd. for 5.2 million yuan through its wholly-owned subsidiary Changsha Sanji Biotechnology Co., Ltd.[19] - The company granted 3 million restricted shares to its chief scientist Herbert Wilhelm Ulmer at a price of 1.00 yuan per share as part of its 2023 restricted stock incentive plan[19] Operational Efficiency - The company's cash flow from operating activities showed a positive trend, indicating improved operational efficiency compared to the previous year[31] - Financial expenses decreased by 77.27% to -¥1,281,367.91, attributed to a reduction in interest income[10] - Research and development expenses increased to ¥11,097,533.95 from ¥10,738,557.48, showing a rise of 3.4%[27] - Other income increased by 295.35% to ¥3,157,658.46, mainly due to an increase in government subsidies related to production operations[10] - The company experienced a foreign exchange loss of ¥1,747,511.93 during the quarter[31]

关于举行 2022 年年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 博爱新开源医疗科技集团股份有限公司（以下简称"公司"）2022 年年度 报告已于今日发布，为使广大投资者对公司 2022 年年度经营情况有更好的了解， 公司将定于 2023 年 5 月 12 日（星期五）15:00-17:00 在深圳证券信息有限公司 提供的网上平台举行 2022 年年报说明会，本次说明会将采用网络远程的方式进 行，投资者可登陆投资者互动平台 http://irm.p5w.net/参与本次说明会。 出席本次说明会的人员有：董事长、总经理张军政先生、副董事长杨洪波先 生、独立董事方拥军先生、董事会秘书邢小亮先生、财务总监刘爱民先生。 证券代码：300109 证券简称：新开源 公告编号：2023-060 博爱新开源医疗科技集团股份有限公司 为进一步做好中小投资者保护工作，增进投资者对公司的了解和认同，以提 升公司治理水平和企业整体价值，现就 2022 年度网上业绩说明会提前向投资者 征集相关问题，欢迎广大投资者于 2023 年 5 月 11 日（星期四） ...

中勤万信会计师事务所（特殊普通合伙） 地址：北京西直门外大街 112 号阳光大厦 10 层 电话：（86-10）68360123 传真：（86-10）68360123-3000 邮编：100044 关于对博爱新开源医疗科技集团股份有限公司 关注函的回复 深圳证券交易所创业版公司管理部： 贵部《关于对博爱新开源医疗科技集团股份有限公司的关注函》（创业板关 注函【2023】第 20 号）收悉，对于贵部询问的有关事项，我所非常重视，经认 真查询，现将核查情况回复如下： 2023 年 1 月 13 日，你公司披露《关于前期股权处置收益调整的公告》，前 期你公司与 Abcam 达成和解，Abcam 对你公司的股权处置款最终结算减少 1,800 万美元，你公司调整前期股权处置收益，将该事项会计处理计入 2021 年。 交易价格分为交易基础对价以及交易价格调整项。交易基础对价为 3.4 亿美 元。交易价格调整项为在交易基础对价 3.4 亿美元基础上加净营运资本差额；加 现金及现金等价物；减应付而未付的交易费用；减有息负债。除交易价格调整项 外，《股权收购协议》还约定了在保证金交付期间的赔偿事项，赔偿事项包含主 要为公司提交 ...

证券代码： 300109 证券简称：新开源 博爱新开源制药股份有限公司投资者关系活动记录表 编号：2015-1218 | --- | --- | --- | |----------------|-------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 招商证券研究发展中心： 黄景文 | | | 人员姓名 | | | | 时间 | 2015 年 12 月 18 | 日上午 | | 地点 | 公司董事会办公室 | | | 上市公司接待人 | 董事会秘书：张军政 | | | 员姓名 | | | | 投资者关系活动 | 1 | 、问：公司四季度整体生产、销售情况如何？ | | 主要内容介绍 | 答：公司下半年受抗战胜利 ...

证券代码： 300109 证券简称：新开源 博爱新开源制药股份有限公司投资者关系活动记录表 编号：2015-0112 1 | --- | --- | --- | |----------------|----------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 国金证券：郭妮妮 汇添富基金：李涛 | | 人员姓名 | 上海彤源投资：梁浩 | 中国民族证券：纪纲、黄景文、田俊峰 | | | 东兴证券：宋凯 | | | 时间 | 2015 年 1 月 12 | 日上午 | | 地点 | 公司三楼会议室 | | | 上市公司接待人 | | 董事会秘书：张军政、副董事长：王坚强，呵尔医疗：毛海 | | 员姓名 | | 湛，三济生物：王 ...

证券代码： 300109 证券简称：新开源 博爱新开源制药股份有限公司投资者关系活动记录表 编号：2016-0628 | --- | --- | --- | |-----------------------|------------------------------|------------------------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 国元证券股份有限公司 陈冠雄 | | | 人员姓名 | | | | 时间 | 2016 年 6 月 28 日 | | | 地点 | 新开源董事会办公室 | | | | | | | 上市公司接待人 员姓名 | 邢小亮 | | | 投资者关系活动 | 一、 参观工厂 | | | 主要内容介绍 | 二、 现场交流 | | | | 1 、问 ...